Letter Agreement for Extension of Collaborative Research Agreement between Pfizer Inc. and Xenogen Biosciences, Inc.

/s/ Stephen J. McAndrew

Summary

This letter agreement, dated December 7, 2004, is between Pfizer Inc. and Xenogen Biosciences, Inc. It confirms Pfizer's decision to extend their existing Collaborative Research Agreement, originally dated September 30, 2001, for one additional year. The extension is made under the terms of the original agreement and a prior amending letter, with all other terms remaining unchanged. Pfizer retains the right to exercise two further one-year extensions in the future. Both parties have signed to acknowledge and accept the extension.

EX-10.3 4 dex103.htm LETTER AGREEMENT BETWEEN REGISTRANT AND PFIZER INC. Letter Agreement between Registrant and Pfizer Inc.

EXHIBIT 10.3


		Groton Laboratories Pfizer Inc Eastern Point Road MS 8200-30 Groton, CT 06340 Tel ###-###-#### Fax ###-###-#### Email *@*
		Global Research & Development

December 7, 2004		Mark P. DellaPorta Senior Director Site Head, Groton Strategic Alliances

Dr. Stephen J. McAndrew

Xenogen Biosciences

5 Cedar Brook Drive

Cranbury, New Jersey 08512

Dear Dr. McAndrew,

Pursuant to Section 3.1(c) of the Collaborative Research Agreement dated September 30, 2001 (“2001 Agreement”) and the Amending Letter dated December 26, 2003 (“Amending Letter”) between Pfizer Inc (“Pfizer”) and Xenogen Biosciences (“Xenogen Cranbury”), Pfizer hereby exercises it’s option to extend the 2001 Agreement for one additional year. This Letter serves as notice of Pfizer’s exercise of the first extension while noting that there are two additional extension options available to Pfizer to exercise in subsequent years.

All other terms and conditions of the 2001 Agreement and the Amending Letter shall remain unchanged and in full force.

Please have the appropriate official of Xenogen Cranbury sign both copies of this Agreement and return one original to Kelly P. Longo at the above address.

Sincerely,

/s/ Mark P. DellaPorta

Mark P. DellaPorta

Site Director

Strategic Alliances

Agreed:

Xenogen Biosciences, Inc.